Cardiovascular risk factors and serious health events in individuals with eating disorders: a systematic review
Abstract
Background: This systematic review aimed to determine how cardiovascular risk factors are associated with serious adverse health events in individuals with eating disorders, aiming to inform clinical decision-making about hospital admission and monitoring.
Main body: We searched 15 multidisciplinary databases from inception to October 2025 following PRISMA guidelines. Eligible studies needed to compare outcomes between individuals with eating disorders who exhibited specific cardiovascular parameters (e.g., resting heart rate, blood pressure, QTc prolongation) and those who did not. Eligible outcomes were serious adverse health events, including death, cardiac arrest, malignant arrhythmias and/or cardiac failure. Of 14,034 de-duplicated records, six studies met inclusion criteria, all focusing exclusively on anorexia nervosa (AN). Only two provided high-confidence evidence. Hypotension at admission was associated with 8.65-fold increased likelihood of in-hospital mortality (95% CI 5.45, 13.7). Composite cardiac complications predicted 3.29-fold increased odds of mortality (95% CI 1.27, 8.55). The evidence for QTc prolongation was insufficient and for the presence of bradycardia was low confidence. Postural hypotension, postural tachycardia, resting tachycardia, and heart rate variability were not examined in any eligible study.
Conclusion: Limited evidence exists for the predictive validity of most cardiovascular parameters for serious adverse health events in eating…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.